STAR-LLD
A Protocol to Assess the Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Administration of Low-dose Lenalidomide (STAR-LLD) for the Treatment of Multiple Myeloma (MM)
Arms / Cohorts
Experimental:Arm 1: Lenalidomide 400 mcg/h
Accepting patients
Experimental:Arm 2: Lenalidomide 300 mcg/h
Accepting patients
Experimental:Arm 3: Lenalidomide 500 mcg/h
Accepting patients
Experimental:Arm 4: Lenalidomide 600 mcg/h
Accepting patients
Active Comparator:Arm 5: Lenalidomide (Oral Capsule Control)
Accepting patients
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.